Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...
Opsynvi is a combination of macitentan, an endothelin receptor antagonist, and tadalafil, a phosphodiesterase 5 inhibitor. The Food and Drug Administration (FDA) has approved Opsynvi ® (macitentan and ...
With many pulmonary arterial hypertension (PAH) patients already taking Johnson & Johnson’s Opsumit (macitentan) or United Therapeutics' Adcirca (tadalafil), J&J has been pursuing a potential ...
OPSYNVI ® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical ...
With the FDA expected this week to approve a first-in-class treatment from Merck for pulmonary arterial hypertension (PAH), Johnson & Johnson has beaten its New Jersey rival to the punch with a nod ...
Johnson & Johnson has announced that its Opsynvi (macitentan and tadalafil) has been approved by the US Food and Drug Administration (FDA) to treat adult patients with pulmonary arterial hypertension ...
FDA approved macitentan/tadalafil (Opsynvi) as the first single-tablet combination therapy targeting multiple pathways for pulmonary arterial hypertension (PAH), Johnson & Johnson announced. The fixed ...
In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results